$48.11
8.21% yesterday
NYSE, Sep 04, 10:19 pm CET

Hims & Hers Health Inc. Stock News

Positive
Seeking Alpha
5 days ago
Hims & Hers is fundamentally undervalued, trading at a forecast P/S ratio of 3.5 despite strong 88% YoY growth and European expansion. Low valuation and scaling by ZAVA lead to a buy rating. Short interest remains high, but a squeeze is unlikely; technicals show strong support at $41, signaling a favorable buy zone.
Positive
Seeking Alpha
6 days ago
Hims & Hers is evolving into a robust health platform, showing strong subscriber growth, rising ARPU, and expanding into weight loss, hormone health, labs, and international markets. Q2 results confirm rapid scaling, with 73% YoY revenue growth, high retention, SaaS-like payback, and reaffirmed guidance despite headline noise and regulatory shifts. The weight loss strategy is diversified beyond...
Neutral
GlobeNewsWire
8 days ago
The suit claims Hims misled investors by overstating its partnership with Novo Nordisk and access to Wegovy, causing stock losses when the truth emerged.
Neutral
GlobeNewsWire
10 days ago
Bragar Eagel & Squire, P.C. Litigation Partners Brandon Walker and Marion Passmore Encourage Investors Who Suffered Losses In Hims To Contact Them To Discuss Their Options
Neutral
Business Wire
10 days ago
NEW YORK--(BUSINESS WIRE)---- $HIMS #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) and reminds investors of the August 25, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Far...
Neutral
PRNewsWire
11 days ago
NEW YORK , Aug. 25, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Hims & Hers Health, Inc. (NYSE: HIMS). Shareholders who purchased shares of HIMS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Neutral
PRNewsWire
11 days ago
LOS ANGELES , Aug. 25, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Hims & Hers Health, Inc. ("Hims & Hers" or "the Company") (NYSE: HIMS) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to inves...
Neutral
GlobeNewsWire
11 days ago
SAN FRANCISCO, Aug. 24, 2025 (GLOBE NEWSWIRE) -- Investors who lost money in Hims & Hers (NYSE: HIMS) are being urged to actively participate in a securities class action lawsuit. The lawsuit alleges that Hims made misleading statements about its GLP-1 weight-loss drug business and its partnership with Novo Nordisk, which was abruptly canceled.
Show more news

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today